Please ensure Javascript is enabled for purposes of website accessibility
Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

Why Eli Lilly Stock Is Crushing It Today

By George Budwell - Jan 11, 2021 at 9:00AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Investors are cheering Lilly's update in Alzheimer's disease today.

What happened

Shares of the biopharmaceutical giant Eli Lilly ( LLY 0.44% ) jumped by as much as 20% in pre-market trading Monday morning. The drugmaker's shares are shooting higher in response to a positive clinical update for its experimental Alzheimer's disease drug known as donanemab.

Donanemab is an experimental antibody designed to target a modified form of beta amyloid. In a midstage trial, the drug reportedly produced a statistically significant slowing in the decline in both cognition and daily function in patients with early symptomatic Alzheimer's disease, when compared to individuals receiving a placebo. 

A young woman and an elderly man viewing a book of photos on a white couch.

Image source: Getty Images.

So what

There are no treatments approved by the Food and Drug Administration that can slow cognitive decline in Alzheimer's disease patients. So, with an estimated 5.5 million Americans currently living with this deadly neurodegenerative disorder, the first drug approved for this indication is widely believed to have a real shot at generating annual sales in excess of $10 billion at peak.

This quantum leap in Lilly's valuation clearly reflects the enormous commercial potential of this untapped drug market. At one point in pre-market trading today, the American pharma titan added a whopping $31.2 billion to its market capitalization.  

Now what

Is Lilly's stock still a buy after this hefty jump? While this pharma stock has been a big winner for investors in the past, this jaw-dropping rise in its market cap probably isn't justified. Scores of similar Alzheimer's disease drugs have shown promise in early- to midstage trials, only to flop badly in pivotal studies. In other words, investors are likely overreacting, perhaps wildly so, to this data release.  

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis – even one of our own – helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Eli Lilly and Company Stock Quote
Eli Lilly and Company
$249.13 (0.44%) $1.09

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 12/02/2021.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Our Most Popular Articles

Premium Investing Services

Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.